NLRP3-IN-17 (compound 15) (3 mg/kg; po) displays desired PK profile, the AUC, t and F% values are 4.2 μg.h/mL, 2.91 h, and 56%, respectively[1].
NLRP3-IN-17 (10 mg/kg; po; single dosage) significantly inhibit NLRP3 dependent IL-1β secretion in acute in vivo LPS+ATP
challenged model in female C57BL/6 mice, it decreases the IL-1β levels by 44%[1].